Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERN/LRPT in South and Southeast Asians with Dyslipidemia
NCT01414166Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of laropiprant + niacin in dyslipidemia, sponsored by Merck & Co.. Started Sep 2011; status: terminated.
02
Drugs
laropiprant + niacin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01414166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414166.